Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Debt to Equity: 2010-2024

Historic Debt to Equity for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $0.33.

  • China Pharma Holdings' Debt to Equity fell 37.79% to $0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.17, marking a year-over-year decrease of 22.39%. This contributed to the annual value of $0.33 for FY2024, which is 4.15% down from last year.
  • China Pharma Holdings' Debt to Equity amounted to $0.33 in FY2024, which was down 4.15% from $0.34 recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Debt to Equity ranged from a high of $0.72 in FY2021 and a low of $0.33 during FY2024.
  • Its 3-year average for Debt to Equity is $0.41, with a median of $0.34 in 2023.
  • Its Debt to Equity has fluctuated over the past 5 years, first skyrocketed by 95.68% in 2021, then tumbled by 39.98% in 2023.
  • Over the past 5 years, China Pharma Holdings' Debt to Equity (Yearly) stood at $0.37 in 2020, then surged by 95.68% to $0.72 in 2021, then declined by 20.90% to $0.57 in 2022, then crashed by 39.98% to $0.34 in 2023, then fell by 4.15% to $0.33 in 2024.